Translational science moves basic research findings to safety and effectiveness testing and ultimately into the hands of clinicians and patients. However, navigating the transition from discoveries made in the lab to new medical products available to patients can be challenging, especially for academic researchers. The National Heart Lung and Blood Institute recently launched the Catalyze program to empower and support translational research through a comprehensive suite of funding, technical services, training, and mentorship to translational investigators working across NHLBI’s entire heart, lung, blood, and sleep portfolio.
The NHLBI Catalyze Program strives to anticipate the needs of a supported project, pivot funding and other support as needed, and prevent projects from failing for non-technical reasons. Projects supported by NHLBI Catalyze receive funding, project management support, access to technical services and expertise, advisory services (IP, regulatory, commercialization), training opportunities, access to best practices and the opportunity to become part of an innovation network.
The NHLBI Catalyze Program funding initiatives support product development, including product definition, pre-clinical research and development from post-discovery to Phase I trial readiness, and enabling technologies and transformative platforms that address heart, lung, blood and sleep diseases and disorders.